LENZ vs. ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, PTCT, ACLX, and AKRO
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), Arcellx (ACLX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
LENZ Therapeutics vs. Its Competitors
ACADIA Pharmaceuticals (NASDAQ:ACAD) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.
ACADIA Pharmaceuticals has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals presently has a consensus price target of $29.06, suggesting a potential upside of 19.99%. LENZ Therapeutics has a consensus price target of $49.60, suggesting a potential upside of 23.95%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than ACADIA Pharmaceuticals.
In the previous week, ACADIA Pharmaceuticals had 17 more articles in the media than LENZ Therapeutics. MarketBeat recorded 20 mentions for ACADIA Pharmaceuticals and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.58 beat ACADIA Pharmaceuticals' score of 1.16 indicating that LENZ Therapeutics is being referred to more favorably in the news media.
ACADIA Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
ACADIA Pharmaceuticals has a net margin of 21.80% compared to LENZ Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat LENZ Therapeutics' return on equity.
96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
ACADIA Pharmaceuticals beats LENZ Therapeutics on 13 of the 16 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LENZ) was last updated on 9/10/2025 by MarketBeat.com Staff
Free LENZ Stock Alerts